IMPACT Medicom

IMPACT Medicom

By IMPACT MedicomScience
Download on the App Store

IMPACT Medicom episodes

  • Live from CCOLD: Dr Davids Discusses the ALPINE Trial in CLL

    In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the results of the ALPINE trial with Dr. Matthew Davies. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. In this episode, Dr. Davids discusses the impact of the results of the ALPINE trial for clinical practice given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory CLL and SLL.

    Our Guest:
    Dr Davids is the Director of Clinical Research at the Division of Lymphoma at the Dana Farber Institute and Associate Professor of Medicine at Harvard Medical School.

    Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.

    This podcast episode was sponsored by BeiGene Canada ULC.

    If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

    18 min
  • Precision Medicine Series: Ep13: Biomarkers in Endometrial Cancer

    Welcome to our 13th podcast episode in the Precision Medicine Series. In this episode, hosted by Anna Christofides,  we discuss diagnostic, prognostic and predictive biomarkers for the treatment of endometrial cancer. 

    Our Guests:

    • Dr. Jessica McAlpine, a Gynaecologic Oncologist and Division Head in the Division of Gynaecologic Oncology at the University of British Columbia
    • Dr. Mary Kinloch, a Gynaecologic Pathologist and Division Head of Pathology and Laboratory Medicine at the University of Saskatchewan 

    This podcast episode was sponsored by Merck Canada.

     If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

    36 min
  • Highlights from ASH: Canadian Perspective on the ALPINE Trial in CLL

    Live From ASH, New Orleans:
    In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the American Society of Hematology meeting in New Orleans. 


    Our Guest:
    Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. In this episode, Dr. Sehn discusses the impact of the results of the ALPINE trial for clinical practice in Canada given the achievement of superior progression-free survival of zanubrutinib over ibrutinib for the treatment of relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

    Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.

    This podcast episode was sponsored by BeiGene Canada ULC.

    If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

    16 min
  • ASH Highlights - ALPINE Trial Shows Improved Efficacy and Safety Profile of Zanubrutinib vs Ibrutinib in CLL

    Live From ASH, New Orleans:
    In this episode, Dr. Jennifer Brown discusses results of the phase 3 ALPINE trial, presented as a late breaking abstract at the American Society of Hematology (ASH) meeting 2022 in New Orleans, LA.

    Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582.

    Our Guest:
    Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.

    This podcast episode was sponsored by BeiGene Canada ULC.

    If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

    15 min
  • Emerging Treatments for Advanced, Unresectable Biliary Tract Cancer

    In this episode we discuss current and emerging systemic treatments for advanced, unresectable biliary tract cancers, as well as the barriers to accessing new treatments in Canada. 

    Our Guest:
    Dr. Howard Lim is a Medical Oncologist, specializing in the treatment of gastrointestinal cancers at the BC Cancer Agency in Vancouver and Clinical Associate Professor in the Faculty of Medicine at the University of British Columbia. 

    This podcast episode was sponsored by AstraZeneca Canada.

    If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

    15 min
  • Precision Medicine in Oncology Podcast Series: Ep12. Biomarkers for the treatment of breast cancer

    Welcome to our 12th episode in the precision medicine in oncology podcast series. In this episode we discuss diagnostic, prognostic and predictive biomarkers for the treatment of breast cancer.

    Our Guest:
    Our guest for this episode is Dr. David Cescon,  a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Ontario, where his clinical practice is devoted to the care of patients with breast cancer.  

    This podcast episode was sponsored by Merck Canada.

     If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

    38 min
  • COVID-19 Pre-Exposure Prophylaxis - Ep4: Protecting Immunocompromised Patients

    Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this third episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with cancer who are not able to mount a sufficient antibody response to vaccination.
     
    Our Guest:
    Our guest  is Dr. Cowan, who is an Associate Scientist at The Ottawa Hospital Research Institute and Assistant Professor at The University of Ottawa. Dr. Cowan is also cross-appointed as an Assistant Professor at the Department of Biochemistry, Microbiology and Immunology and a Physician for the Division of Infectious Diseases at The Ottawa Hospital in Ontario. Her clinical and research focus is on prevention of infection in immunocompromised patients

    Sponsored by AstraZeneca Canada

    If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

    23 min
  • COVID-19 Pre-Exposure Prophylaxis - Ep3: Patients with Cancer

    Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this third episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with cancer who are not able to mount a sufficient antibody response to vaccination.
     
    Our Guest:
    Our guest  is Dr. Dimas Yusuf, Medical Oncologist and specialist in general internal medicine at Pacific Specialty Care in Delta, BC. He is also the Managing Director of OncoCare Health Incorporated in Vancouver, BC, which delivers cutting edge technologies and insights to advance cancer care. 

    Sponsored by AstraZeneca Canada

    If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

    36 min
  • COVID-19 Pre-Exposure Prophylaxis - Ep2: Patients with Hematological Malignancies

    Welcome to IMPACT Medicom’s podcast series on COVID-19 prophylaxis. In this second episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with hematological malignancies who are not able to mount a sufficient antibody response to vaccination.
     
    Our Guest:
    Our guest  is Dr Laurie Sehn, Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer in Vancouver, British Columbia. 

    Sponsored by AstraZeneca Canada

    If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

    15 min
  • COVID-19 Pre-Exposure Prophylaxis - Ep1: A pharmacist perspective (French)

    Bienvenue dans la série de balados d’IMPACT Medicom sur la prophylaxie contre la COVID-19.
     
    Notre invitée
    Notre invitée dans l’épisode d’aujourd’hui est Annick Dufour, chef adjointe au département de pharmacie du CISSS Montérégie-Centre, au Québec au niveau des soins pharmaceutiques, de la recherche clinique et de l’oncologique.  Elle est pharmacienne en oncologie depuis plusieurs années. Elle est également présidente du Comité d’évolution de la pratique des soins pharmaceutiques (CEPSP) du programme québécois de cancérologie du ministère de la Santé et des Services sociaux (MSSS) 

    Sponsored by AstraZeneca Canada

    If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

    22 min

About IMPACT Medicom

From the publisher's feed

We are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic…

More shows like IMPACT Medicom

The Daily by The New York Times

The Daily

112,266 Listeners